Klinikgruppe Dr. Guth GmbH & Co. KG

At Klinikgruppe Dr. Guth GmbH & Co. KG, researchers are evaluating novel therapeutic technologies aimed at improving organ protection during high‑risk procedures.

• Evaluation of angiotensin II as a primary vasopressor
• Assessment of device‑guided hemodynamic management
• Development of diagnostic algorithms for early kidney injury detection
• Integration of advanced monitoring in cardiac surgery

These studies support the site’s commitment to advancing analytical and therapeutic techniques that can reduce complications such as acute kidney injury in cardiovascular settings.

The clinic’s cardiovascular program concentrates on chronic kidney disease, hypertension, and related heart outcomes, seeking better treatment strategies.

• Investigation of combined therapy with baxdrostat and dapagliflozin
• Exploration of blood pressure control on renal progression
• Study of cardiovascular death and heart‑failure events in CKD patients
• Monitoring of eGFR decline and kidney failure risk

Through these trials, the site aims to improve long‑term health for patients with chronic kidney disease and high blood pressure, aligning with European standards for cardiovascular research.